Dual AChE Inhibitor

Dual AChE Inhibitor is an experimental small molecule therapeutic candidate being developed by AVVA Pharmaceuticals. It is designed to inhibit the enzyme acetylcholinesterase (AChE), which is responsible for the degradation of the neurotransmitter acetylcholine in the synaptic cleft. The 'dual' designation in its name typically refers to a mechanism of action that involves binding to both the catalytic active site and the peripheral anionic site of the AChE enzyme. This dual-binding approach is often pursued to achieve more potent enzyme inhibition and to potentially provide neuroprotective effects by interfering with AChE-induced amyloid-beta aggregation, a hallmark of Alzheimer's disease. Alternatively, 'dual' may refer to the simultaneous inhibition of both acetylcholinesterase and butyrylcholinesterase (BChE). The drug is primarily intended for the treatment of cognitive symptoms associated with Alzheimer's disease and other neurodegenerative disorders.

Other names

Dual acetylcholinesterase inhibitor